logo

For the Inventor, By the Inventor

Cambridge, MA, United States of America

Daniel Chasman

This inventor holds 3 USPTO granted patents and 4 published patent applications and 1 EPO patent. Top assignees: The Brigham and Women's Hospital, Inc., Celera Corporation, Applera Corporation. Active years: 2011-2023.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Daniel Chasman. Retrieved from https://idiyas.com/inventor/daniel-chasman-t20a995y

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 3 

% Patents Active = 100.0


Average Co-Inventor Count = 3.0

ph-index = 1

Forward Citations = 3(Granted Patents)


Location History:

  • Somerville, MA (US) (2011)
  • Cambridge, MA (US) (2020 - 2023)

Company Filing History:

goldMedal3 out of 1,425 
 
The Brigham and Women's Hospital, Inc.
 patents
silverMedal2 out of 98 
 
Celera Corporation
 patents
bronzeMedal1 out of 496 
 
Applera Corporation
 patents
where one patent can have more than one assignee

Years Active: 2011-2023

Loading Chart...
Loading Chart...
3 patents (USPTO):Explore Patents
1. 11697850 - Polymorphism in the Apo(a) gene predict responsiveness to acetylsalicylic acid treatment (2023-07-11),
2. 10550433 - Polymorphism in the Apo(a) gene predict responsiveness to acetylsalicylic acid treatment (2020-02-04),
3. 7943317 - Polymorphism in the Apo(a) gene predict responsiveness to acetylsalicylic acid treatment (2011-05-17),

Title: The Innovations of Daniel Chasman

Introduction

Daniel Chasman is a notable inventor based in Cambridge, MA (US). He has made significant contributions to the field of genetics and pharmacogenomics, holding a total of 3 patents. His work primarily focuses on the relationship between genetic polymorphisms and drug responsiveness.

Latest Patents

One of his latest patents is titled "Polymorphism in the Apo(a) gene predict responsiveness to acetylsalicylic acid treatment." This invention relates to nucleotide polymorphisms in the human Apo(a) gene and aims to identify whether a human subject will respond to treatment with acetylsalicylic acid. This innovative approach has the potential to personalize treatment plans based on genetic makeup.

Career Highlights

Throughout his career, Daniel Chasman has worked with esteemed organizations such as The Brigham and Women's Hospital, Inc. and Celera Corporation. His experience in these institutions has allowed him to advance his research and contribute to the understanding of genetic factors in drug response.

Collaborations

Daniel has collaborated with notable colleagues, including Paul M. Ridker and Dov Shiffman. These partnerships have further enriched his research and expanded the impact of his inventions.

Conclusion

Daniel Chasman is a prominent figure in the field of genetics, with a focus on the implications of genetic polymorphisms in drug treatment. His innovative patents and collaborations highlight his commitment to advancing medical science and improving patient care.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…